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2352-345XSUMMARY
Extracellular vesicle is a nanovesicle that shuttles proteins,
nucleic acids, and lipids, thereby inﬂuencing cell behavior. This
article shows that ceramide-triggered extracellular vesicles
work as DNA cargo for hepatitis B virus-DNA and are capable
of trasmitting to naive hepatocytes. Further, this article
demonstrates that the transmission of hepatitis B virus-DNA
via these extracellular vesicles is resistant to antibody
neutralization.
BACKGROUND & AIMS: An extracellular vesicle (EV) is a nano-
vesicle that shuttles proteins, nucleic acids, and lipids, thereby inﬂu-
encing cell behavior. A recent cropof reports have shown thatEVs are
involved in infectious biology, inﬂuencing host immunity and playing
a role in the viral life cycle. In the present work, we investigated the
EV-mediated transmission of hepatitis B virus (HBV) infection.
METHODS: We investigated the EV-mediated transmission of
HBV infection by using a HBV infectious culture system that
uses primary human hepatocytes derived from humanized
chimeric mice (PXB-cells). Puriﬁed EVs were isolated by
ultracentrifugation. To analyze the EVs and virions, we used
stimulated emission depletion microscopy.
RESULTS: Puriﬁed EVs from HBV-infected PXB-cells were shown
to contain HBV DNA and to be capable of transmitting HBV DNA
to naive PXB-cells. These HBV-DNA–transmitting EVs were
shown to be generated through a ceramide-triggered EV
production pathway. Furthermore, we showed that these HBV-
DNA–transmitting EVs were resistant to antibody neutralization;
stimulated emission depletionmicroscopy showed that EVs lacked
hepatitis B surface antigen, the target of neutralizing antibodies.
CONCLUSIONS: These ﬁndings suggest that EVs harbor a DNA
cargo capable of transmitting viral DNA into hepatocytes during
HBV infection, representing an additional antibody-
neutralization–resistant route of HBV infection. (Cell Mol Gas-
troenterol Hepatol 2016;-:-–-; http://dx.doi.org/10.1016/
j.jcmgh.2016.10.003)
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epatitis B virus (HBV) is an infectious agent thathttp://dx.doi.org/10.1016/j.jcmgh.2016.10.003
Hbelongs to the Hepadnaviridae family, whose mem-
bers are characterized by a partially double-stranded circularDNA.1,2 Although an effective HBV preventive vaccine is
available, HBV infection continues to be a major health
concern.3 Approximately 350 million people are chronically
infected by HBV worldwide, and some of these infections will
result in cirrhosis and hepatocellular carcinoma.2,4
There is growing evidence that HBV maturation and
egress depend on intraluminal vesicles of maturing endo-
somes known as multivesicular bodies (MVBs).5–7 HBV core
and L envelope proteins have been shown to interact with
the ubiquitin-interacting adaptor g2-adaptin and the Nedd4
ubiquitin ligase, possibly to regulate transport of the viral
structures through the late endosomal pathway.8,9 In
addition, several studies have shown that Vps4A/B and
Alix/AIP1 (a functional link between endosomal sorting
complexes required for transport (ESCRT)-I and ESCRT-III
in mammalian cells) contribute to HBV release.5,6 Thus,
HBV virions are thought to bud into late endosomes or
MVBs by using ESCRT/Vps4B functions, subsequently exit-
ing the cell by the extracellular vesicle (EV) pathway.
EVs fall into 2 general categories based on biogenetic
deﬁnition.10 One category generally is referred to as the
exosome, which consists of 30- to 100-nm diameter nano-
vesicles that originate from the intraluminal vesicles of
MVBs; the fusion of MVBs with the cell membrane results in
the release of vesicles into the extracellular compartment.11
The other category generally is referred to as microvesicles.
Microvesicles generally are larger than exosomes (40- to
1000-nm diameter) and bud from the cellular membrane.10
Historically, EVs were thought to function primarily in the
removal of unnecessary proteins from the cell. More recent
2 Sanada et al Cellular and Molecular Gastroenterology and Hepatology Vol. -, No. -studies have shown that EVs are involved in multiple bio-
logical processes; under normal and pathologic conditions,
EVs appear to shuttle their contents (including proteins,
lipids, and nucleic acids) among various cells.12–14
Notably, recent studies have shown that EVs play an
important role in infectious disease by mediating the
transfer of pathogen-derived antigens and virulence fac-
tors.15 EVs derived from virus-infected cells contain viral
proteins and viral RNA; the contents of these vesicles are
enclosed in a cellular membrane, thus enabling viruses to
evade host immune response to herpes simplex virus,16,17
human immunodeﬁciency virus,18,19 Epstein–Barr virus,17
and cytomegalovirus20 infection. Furthermore, EVs from
hepatitis A virus or hepatitis C virus–infected hepatocytes
permit the respective viruses to invade and replicate within
host hepatocytes.21,22 However, the role of EVs in HBV
infection still largely is unknown. Speciﬁcally, the lack of
viral culture systems for HBV has hampered the evaluation
of EV-mediated transmission of HBV infection.
In this study, we investigated EV-mediated transmission
of HBV infection in a highly efﬁcient HBV infectious culture
system, for which we used primary hepatocytes derived
from humanized chimeric mice with human livers. We
further elucidated the involvement of ceramide-triggered EV
production in HBV morphogenesis.
Materials and Methods
Ethics Statement
This study was performed in strict accordance with both
the Guidelines for Animal Experimentation of the Japanese
Association for Laboratory Animal Science and the recom-
mendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. All protocols were
approved by the ethics committee of the Tokyo Metropolitan
Institute of Medical Science (license number 15059).Primary Hepatocytes From Humanized
Chimeric Mice: PXB-Cells
Primary human hepatocytes derived from chimeric mice
with human liver (PXB-cells; PhoenixBio, Hiroshima, Japan)
were cultured on type I, collagen-coated, 48-well plates
using maintenance medium as previously described.23
Culture ﬂuids or cells from wells with the same treatment
in a plate were pooled, and then used for analysis.Inocula Used for Infection of Primary
Hepatocytes
Inocula of HBV genotype A or C were derived from
serum obtained from humanized chimeric mouse at 8–10
weeks after infection by the respective virus.Infection of PXB-Cells by HBV
PXB-cells were inoculated with HBV at 5 genome
equivalents (GEq) per cell. Inoculated cells were washed at
1 and 2 days after infection, and culture medium was
collected every 5 days thereafter.HBV-DNA Quantiﬁcation
DNA extraction from samples was performed using
SMItest EX-R&D kits (Nippon Genetics, Tokyo, Japan)
according to the manufacturer’s instructions.
Quantiﬁcation of HBV genomic DNA was performed by
quantitative polymerase chain reaction (qPCR) using the
Thunderbird Probe qPCR Mix (Toyobo, Osaka, Japan) CFX96
real-time PCR detection system (Bio-Rad, Hercules, CA).
Ampliﬁcation reaction mixtures (30 mL) contained 5 mL DNA
solution, 200 nmol/L forward primer HB-166-S21 (nucleo-
tides [nts] 166–186; 5’-CACATCAGGATTCCTAGGACC-3’),
200 nmol/L reverse primer HB-344-R20 (nts 344–325;
5’-AGGTTGGTGAGTGATTGGAG-3’), 300 nmol/L TaqMan
(ThermoFisher Scientiﬁc,Waltham,MA) probeHB-242-S26FT
(nts 242–267; 5’-CAGAGTCTAGACTCGTGGTGGACTTC-3’), and
15 mL of Thunderbird Probe qPCR Mix. Thermal cycling con-
ditions were as follows: activation of uracil-N-glycosylase
(UNG) by incubation at 50C for 2 minutes; activation of Taq
polymerase (Nippongene, Toyama, Japan) and inactivation of
UNG by incubation at 95C for 10 minutes; and ampliﬁcation
by 53 cycles of incubation at 95C for 20 seconds and 60C for
1 minutes. The standard curve for this quantiﬁcation was
calculated using a series of 10-fold dilutions (at deﬁned con-
centrations) of a recombinant plasmid into which the HBV
genome had been inserted.
Indirect Immunoﬂuorescence Analysis
Cells were ﬁxed with 10% phosphate-buffered formalin
(pH 7.4) for 10 minutes at room temperature. After washing 3
times with phosphate-buffered saline (PBS; pH 7.4), cells were
permeabilized with 0.25% Triton X-100 (Nacalai Tesque,
Kyoto, Japan) for 10 minutes at room temperature. Viral anti-
gen was stained with antibody to hepatitis B surface antigen
(anti-HBs) rabbit serum (1:300) and Alexa-488–conjugated
anti-rabbit IgG (Thermo Fisher Scientiﬁc). Nuclei also were
stained using 4’,6-diamidino-2- phenylindole.
In Situ Hybridization
PXB-cells were ﬁxed in 4% buffered paraformaldehyde
(pH 7.5) for 1 hour at room temperature. After washing 3
times with PBS, the cells were treated with 0.25% Triton
X-100 for 10 minutes at room temperature. To detect HBV
DNA, in situ hybridization was performed as described
previously using fragmented RNA probes synthesized from
a full-length HBV genome.24
EV Isolation
The cultureﬂuids ofPXB-cellswere centrifugedat2000 g
for 10 minutes at 4C. To remove further cellular debris, the
supernatants were centrifuged at 12,000 g for 30minutes at
4C, and then ﬁltered through a 0.22-mm ﬁlter. The resulting
ﬁltered culture supernatant (designated as Sup in experi-
ments) then was processed for isolation of EVs as follows. Sup
was ultracentrifuged at 110,000 g for 70minutes at 4C. The
resulting supernatants were decanted and retained separately
for subsequentuse (see later) as the fractionwithoutEVs (EV-).
Meanwhile, the ultracentrifugation pellets were resuspended
in PBS and subjected to a second round of ultracentrifugation
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were discarded, and the pellets were resuspended in PBS,
yielding the EV fraction (EVþ) used for subsequent analyses.
RNA Extraction and Analysis
Total RNA was extracted from the PXB-cells and from the
liver of humanized chimeric mouse using the RNeasy Mini Kit
(Qiagen, Hilden, Germany). Expression of messenger RNAs
(mRNAs) in PXB-cells was determined by an Agilent Human
GeneExpression 4 44k v2microarray (Agilent Technologies,
Santa Clara, CA). Expression of mRNAs in the liver of human-
ized chimeric mouse was determined by mRNA sequencing
(Illumina HiSeq; Illumina, San Diego, CA). The expression of
neutral sphingomyelinase (nSMase) 1, 2, and 3 were deter-
mined by TaqMan Gene Expression Assays (nSMase1,
Hs00162006_m1; nSMase2, Hs00920354_m1; and nSMase3,
Hs00215775_m1; Thermo Fisher Scientiﬁc).
Total RNA was extracted from the culture ﬂuid and EV
fractions using SepaGene RV-R (Eidia, Tokyo, Japan), and
reverse-transcribed using the High-Capacity Complementary
DNA Reverse Transcription Kit (Thermo Fisher Scientiﬁc)
according to the manufacturer’s protocol. Viral complemen-
tary DNA then was quantiﬁed by qPCR as described earlier.
Immunoprecipitation
Each aliquot (200 mL at 3.0 104 viral DNA copies/mL) of
Sup, EV-, and EVþ fractions from primary human hepatocytes
was mixed with an equal volume of PBS containing 1% bovine
serumalbumin (BSA) and5mgof oneof the following: anti-CD9
antibody (M-L13; Becton, Dickinson and Company, Franklin
Lakes, NJ), anti-CD63 antibody (MEM-259; Abcam, Cambridge,
UK), anti-CD81 antibody (JS-81; Becton, Dickinson and Com-
pany), or anti-hemagglutinin (HA) tag antibody (12CA5(2);
BioVision, San Francisco, CA), or with diluted serum (1:300)
from a normal (HBV-naive) or HBs-immunized mouse. The
resulting mixture was incubated for 16 hours at 4C. Each
ﬂuid þ antibody mixture then was combined with 50 mL of a
50% slurry of protein G–Sepharose 4 Fast Flow (GE Health-
care, Chicago, IL) and incubated with rotation at 4C for 2
hours. The mixtures were centrifuged at 2300  g for 20
seconds at 4C, and the supernatants were discarded. The
pellets were washed twice with 1% BSA in 10% Dulbecco’s
modiﬁed Eagle medium. The pellets thenwere resuspended in
10% Dulbecco’s modiﬁed Eagle medium containing 1% BSA
and used for quantiﬁcation analysis of HBV DNA.
Treatment With GW4869
PXB-cells were infected with HBV. At 22 days post-
infection, the cells were incubated with culture medium
containing GW4869 (Merck Millipore, Billerica, MA) at the
indicated concentrations. After 4 days’ incubation, the cul-
ture ﬂuid and cells were collected, pooled, and used for
analysis of the HBV-DNA titer.
Inoculation of HBV From Each Fraction
to PXB-Cells
The Sup was collected from the HBV-infected PXB-cells.
The EVþ and the EV- fractions were prepared as describedearlier. PXB-cells were inoculated with 5 GEq/cell of HBV
derived from the Sup, EVþ, or EV- fractions.
Neutralization Test
For time-course analysis, a volume of the supernatant
containing 2  106 HBV-DNA copies was incubated with 1
IU hepatitis B immune globulin (HBIG; Mitsubishi Tanabe
Pharma Corporation, Osaka, Japan) in 500 mL of culture
medium for 1 hour at room temperature. Naive PXB-cells
were cultured with the HBIG-pretreated culture supernatant
for 2 or 24 hours. After the incubation period, the cells were
collected, pooled, and used for analysis.
For neutralization analysis of Sup, EV-, and EVþ frac-
tions, HBV-vaccinated human serum or AB human serum
(Pel-Freez Biologicals, Rogers, AR) diluted 1:10 in culture
medium was mixed with an equal volume of Sup, EVþ, or
EV- containing 2.0  106 viral DNA copies. These mixtures
were incubated at 37C for 1 hour, and then 250 mL of each
mixture was used to inoculate a PXB-cell culture (4.0  105
cells, 5 GEq/cell). For analysis of viral entry, at 3 hours after
infection, the cells were washed 5 times with PBS and then
collected for analysis. For long-term analysis, the cells were
washed at 1 and 2 days postinfection and the culture ﬂuid
was harvested every 5 days thereafter. Collected culture
ﬂuids were pooled and used for qPCR analysis.
Scanning Electron Microscopy
Samples for scanning electron microscopy were pre-
pared by spotting of microvesicles (suspended in 0.1% PBS)
onto poly-L-lysine–coated (Sigma-Aldrich, St. Louis, MO)
coverslips. The samples were ﬁxed with 2.5% glutaralde-
hyde in 0.1 mol/L phosphate buffer ﬁxative solution for 30
minutes at room temperature and then washed 3 times with
0.1 mol/L phosphate buffer solution. The samples were
immersed in a 1% (wt/vol) OsO4 solution for 1 hour at 4C,
then dehydrated in a graded ethanol series and transferred
to t-butyl alcohol. The samples were dried in a freeze dryer
(Hitachi ES-2020; Hitachi High-Tech Fielding Corporation,
Tokyo, Japan), coated with OsO4 for 1 minute using an
osmium plasma coater (NL-OPC80; Nippon Laser and Elec-
tronics Laboratory, Aichi, Japan), and examined using a
Hitachi S-4800 ﬁeld emission scanning electron microscope
at an accelerating voltage of 10 kV.
Stimulated Emission Depletion Microscopy
Samples of the culture ﬂuid or EVs were ﬁxed with 4%
paraformaldehyde on poly-L-lysine–coated coverslips for 30
minutes at room temperature. The samples were washed
twice with PBS; incubated with 50 mmol/L NH4Cl for 10
minutes at room temperature; washed twice with PBS;
permeabilized with 50 mg/mL digitonin for 10 minutes at
room temperature; washed twice with PBS; treated with
0.25% Triton X-100 for 10 minutes at room temperature;
washed twice with PBS; and blocked with blocking buffer
(1% BSA and 1 mmol/L EDTA in PBS) at 4C overnight. The
slides then were incubated with primary antibodies for 2
hours at room temperature. The primary antibodies were
used at the following concentrations or dilutions: anti-CD81
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mL; anti–hepatitis B core antigen (anti-HBc) mouse serum,
1:100; anti-HBs rabbit serum, 1:600. The slides were
washed 5 times with PBS containing 0.05% Tween 20 and
then incubated with 40 mg/mL secondary antibody (Alexa
488– or Alexa 555–conjugated anti-mouse, anti-rabbit, or
streptavidin; Thermo Fisher Scientiﬁc) for 2 hours at room
temperature. After washing, the specimens were mounted
using Prolong Diamond (Thermo Fisher Scientiﬁc) and
examined using a TCS SP8 stimulated emission depletion
(STED) 3 microscope (Leica Microsystems, Wetzlar,
Germany).DNase I Treatment
The DNase I reaction mixture consisted of 26 mL of Sup,
EV-, or EVþ fractions (or extracted DNA as a control), 1 mL
of DNase I (10 U/mL; GE Healthcare), and 3 mL of DNase I
buffer. The mixture was incubated at 37C for 10 minutes.
The reaction mixture then was incubated at 75C for 10
minutes to heat-inactivate the DNase I. DNA extraction from
samples was performed using SMItest EX-R&D kits (Nippon
Genetics) according to the manufacturer’s instructions, and
viral DNA was quantiﬁed by qPCR as described earlier.Statistical Analysis
Statistical analyses were performed with Prism software
(version 6.0; GraphPad, GraphPad Software, La Jolla, CA).
Statistical signiﬁcance was determined by using 2-tailed
1-way analysis of variance with a post hoc Bonferroni
or Mann–Whitney U test. P values less than .05 were
considered signiﬁcant.
Results
Primary Hepatocytes Derived From Humanized
Chimeric Mice Support HBV Propagation
Several in vitro studies have reported that HBV can
infect the primary hepatocytes derived from human and
tree shrew, or any of several cell lines.25 Here, to evaluate
EV-mediated HBV transmission, we used primary hepato-
cytes derived from humanized chimeric mice with human
livers (PXB-cells).23 First, we examined whether PXB-cells
supported HBV propagation. As indicated in the schematic
protocol (Figure 1A), supernatant was collected for 42 days
after infection with HBV; both genotypes A and C were
tested (separately). HBV DNA in the resulting culture
supernatants was measured by real-time qPCR. Both geno-
types of HBV propagated well in PXB-cells and the viral DNA
level in culture ﬂuid reached approximately 107–108
copies/mL (on day 42) (Figure 1B). Furthermore, immu-
noﬂuorescent analysis and in situ hybridization analysis
showed that HBV infected approximately 75% of the
PXB-cells on day 41 (Figure 1C).
Next, we tested if supernatant from HBV-infected
PXB-cell culture showed infectivity for naive PXB-cells.
The time-course analysis of the supernatants obtained from
the supernatant-infected cells showed that HBV-DNA levels
increased to approximately 107–108 copies/mL on day 37(Figure 1D). These results indicated that HBV infected and
replicated in PXB-cells, and that the supernatant of HBV-
infected PXB-cells showed the same infectivity of naive
PXB-cells as the serum of HBV-infected humanized chimeric
mice. We next used this system to examine EV-mediated
HBV transmission.
EVs Isolated From HBV-Infected Primary
Hepatocytes Contain HBV DNA
Recent studies have shown that EVs from hepatitis C
virus–, cytomegalovirus-, and Epstein–Barr virus–infected
cells contain RNA and proteins for the respective
viruses.17 However, it still is not known whether EVs can
harbor a viral DNA cargo. To test this possibility, we
assessed whether EVs from the culture supernatant of
HBV-infected PXB-cells contain HBV DNA. qPCR analysis
of the EVþ fraction isolated from HBV-infected PXB-cells
showed that 62.5% ± 39.8% of HBV DNA in the culture
supernatant was carried in the EV fraction (Figure 2A).
The concentrations of HBV RNA in the Sup and in the
EV- fraction were 0.021 ± 0.015 and 0.018 ± 0.016 of
those of HBV DNA in each fraction, respectively, whereas
the corresponding ratio in the EVþ fraction was 0.0018 ±
0.0004 (Figure 2B). We next immunoprecipitated the Sup
with antibodies (anti-CD9, anti-CD63, and anti-CD81)
against representative exosome membrane proteins and
then determined HBV-DNA levels in the immune-
precipitation samples. The HBV-DNA levels of specimen
recovered from immune-precipitation with anti-CD9,
CD63, and CD81 antibodies were 0.84 ± 0.18, 2.08 ±
1.77, and 2.17 ± 0.64, respectively, of that recovered from
immune-precipitation with control antibody (Figure 2C).
These observations are consistent with microarray and
RNA sequencing data (Figure 2D and E), indicating that
CD81 (but not CD9) is highly expressed in HBV-infected
PXB-cells and livers. Next, to analyze what fraction of
HBV virions (Dane particles) and EVs carrying HBV DNA
are contained in the 3 fractions (Sup, EV-, and EVþ), we
immune-precipitated the 3 fractions with antibodies
against HBs and CD81, and then determined HBV-DNA
levels in the immune-precipitation samples. In speci-
mens recovered from immune-precipitation with anti-HBs
antibody, specimens derived from EV- were enriched for
HBV DNA, whereas HBV DNA was not detected in speci-
mens derived from EVþ (Figure 2F). In contrast, speci-
mens recovered from immune-precipitation of EVþ with
anti-CD81 antibody were enriched for HBV DNA
compared with those derived by anti-CD81 immune-
precipitation of Sup or EV- (Figure 2F). Considered
together, the results of this experimental series suggested
that EVs derived from HBV-infected PXB-cells carry viral
DNA as a cargo, but that these particles apparently are
depleted for HBV RNA.
GW4869 Treatment Suppresses the Production
of HBV-DNA–Containing EVs
Next, we investigated the mechanisms that generate HBV-
DNA–containing EVs. Two major pathways have been
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Figure 1. Primary hepatocytes derived from humanized chimeric mice with human livers support HBV propagation. (A)
Experimental schedule of HBV infection of PXB-cells. (B) Time-course studies of the PXB-cells inoculated with chimeric mouse
serum samples positive for HBV genotypes A or C. HBV-DNA levels in supernatants were determined by qPCR (n ¼ 3–4 per
group at each time point). (C) Detection of viral DNA by in situ hybridization (upper) and of HBs antigen by immunoﬂuorescent
assay (lower) from HBV-infected PXB-cells at 41 days postinfection (dpi). Upper: Viral DNA, blue. Lower: HBs antigen, green;
nuclei, blue. (D) Time-course studies of the PXB-cells inoculated with supernatants from HBV-infected PXB-cells (n ¼ 3). (B
and D) Data were pooled from 3 or 4 independent experiments with 1 plate per experiment. (C) The data were reproducible in 3
independent experiments with 1 plate per experiment, and the ﬁgure shown here is a representative one. (B and D) Values are
presented as means ± SDs.
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process,11,26 and the other is a ceramide-triggered process.27
In other work with HBV-infected humanized chimeric mice
(Figure 3A and B), we observed that serum and liver HBV-
DNA levels correlated with accumulation of the transcript
encoding nSMase2, a key enzyme for ceramide-mediated
exosome generation. On the basis of those results, we hy-
pothesized that the production of HBV DNA from HBV-
infected hepatocytes depends on the ceramide-mediated
exosome pathway. To test this prediction, we treated HBV-
infected PXB-cells with GW4869, an nSMase inhibitor that
is known to inhibit ceramide biosynthesis.27,28 Treatment
with GW4869 attenuated HBV-DNA levels in culture super-
natants, but not in hepatocytes (Figure 3C and D). These re-
sults suggested that inhibition of ceramide biosynthesis
suppresses the production of HBV-DNA–containing EVs. In
conﬁrmation of this hypothesis, we observed that GW4869
treatment suppressed the number of EVs visible in electronmicroscopic images of puriﬁed EVs isolated from HBV-
infected PXB-cells (Figure 3E and F). In addition, GW4869
treatment resulted in decreased HBV-DNA levels in the pu-
riﬁed EV fraction when normalized per milliliter of the orig-
inal culture supernatant, consistent with the decrease of the
number of EVs (Figure 3G and H). Considered together, these
results indicated that HBV-DNA–containing EVs are produced
via the ceramide-triggered exosome pathway.STED Microscopic Analysis Shows That EVs
Incorporate CD81 and HBcAg Protein
To clarify whether or not the HBV-DNA–containing EVs
possess viral proteins, we examined the interaction of
hepatitis B surface antigen (HBsAg) and hepatitis B core
antigen (HBcAg) with EVs labeled with anti-CD81 antibody.
The interaction was examined using STED microscopy,
which permits the detection of co-located EVs and viral
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6.0  103 viral DNA copies with each anti-
body (n ¼ 3). Data were pooled from (A–D,
and F) 3 independent experiments with 1
plate per experiment, or (E) from 3 individual
animals. Values are shown as means ±
SDs. Ctrl, control; HA-Tag, hemagglutinin
tag.
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Figure 3.GW4869 treat-
ment suppresses the
secretion of HBV-DNA–
containing EVs. (A and B)
The correlation between
nSMase 1, 2, and 3 and (A)
serum or (B) liver HBV
DNA in HBV-infected hu-
manized chimeric mice
(n ¼ 7). Each symbol rep-
resents a distinct animal.
To measure the strength of
the association, the Pear-
son correlation coefﬁcient
was calculated. (C and D)
HBV-DNA levels (deter-
mined by qPCR) in (C)
culture supernatant and
(D) PXB-cells after
GW4869 treatment (n ¼ 3).
(E and F) Electron micro-
scopic images of puriﬁed
EV fraction isolated from
HBV-infected PXB-cells
treated with (E) vehicle or
(F) GW4869. White bar,
100 nm. (G) The number of
puriﬁed EV and (H) copy
number of HBV DNA in EV
fraction isolated from
HBV-infected PXB-cells
with (þ) or without (-)
GW4869 treatment (10
mmol/L) (n ¼ 3). Data were
pooled from (A and B) 7
individual animals, (C, D,
and H) 3 independent ex-
periments with 1 plate per
experiment, or from (G)
3–4 ﬁelds per experiment,
or (E and F) data were
representative of 3 inde-
pendent experiments with
1 plate per experiment.
Values are shown as (C, D,
and H) means ± SDs or (G)
SEM.
- 2016 Transmission of HBV DNA by EVs 7proteins. Imaging analysis with STED microscopy showed
that CD81 co-localized with HBcAg but not with HBsAg
(Figure 4A and B). Furthermore, the frequency of HBcAgþ
CD81þ spots was 25% that of CD81þ spots, a value com-
parable with that of HBcAgþ HBsAgþ spots (Figure 4E).
These results suggested that HBV-DNA–containing EVs
possess HBcAg, but not HBsAg. This result motivated us toexamine the effect of anti-HBs neutralizing antibody on HBV
entry and replication. We performed a time-course analysis
of PXB-cells inoculated with HBV that had been pretreated
with HBIG (Figure 4F). Neutralizing antibodies decreased
intracellular HBV-DNA level by 70% compared with HBV-
DNA levels in nontreated hepatocytes 2 hours after infec-
tion. Furthermore, in the presence of neutralizing
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Figure 4. Characterization of HBV-containing infectious EVs. (A–D) STED microscopic images of supernatant of HBV-infected
PXB-cells. Scale bars: 2.5 mm. (A) Green, CD81; red, HBcAg; arrowhead, CD81þHBcAgþ spot; inset, enlarged image of
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24 hours after infection increased 3-fold compared with
HBV-DNA levels at 2 hours after infection, and increased
1.6-fold even in the HBIG-treated hepatocytes. These results
suggested that HBV DNA is transmitted and replicates even
in the presence of neutralizing antibodies.EV Fractions Transmit HBV DNA to Primary
Hepatocytes via a Mechanism That Is Resistant
to the Effects of Neutralizing Antibodies
Next, we focused on the transmission of HBV mediated
by EVs. Speciﬁcally, we isolated puriﬁed EVs from the cul-
ture supernatant of HBV-infected PXB-cells, and then used
the EVþ fraction to infect naive PXB-cells; this procedure is
shown schematically in Figure 5A. qPCR analysis conﬁrmedthat this procedure yielded detectable levels of HBV DNA at
3 hours after infection by the EVþ fraction (Figure 5B). We
noted, however, that HBV-DNA levels still were approxi-
mately 10-fold lower after infection with EVþ compared
with levels obtained after infection with Sup or EV- frac-
tions. We inferred that the higher HBV levels observed upon
infection with the Sup and EV- fractions reﬂected the
presence of HBV virions in the Sup and EV- fractions,
and that these virions were removed from the EVþ fraction
via ultracentrifugation. To clarify the effect of ultra-
centrifugation on HBV virions and HBV-DNA–containing
EVs, we examined the number of CD81þHBcAgþ and
HBsAgþHBcAgþ particles using STED microscopy before
and after ultracentrifugation. As shown in Figure 5C, the
number of HBcAgþHBsAgþ spots showed a larger depletion
than that of the HBcAgþCD81þ spots. That is, the number of
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- 2016 Transmission of HBV DNA by EVs 9HBcAgþCD81þ spots was 2.6-fold that of HBcAgþHBsAgþ
spots after ultracentrifugation, suggesting an enrichment for
HBV-containing EVs compared with HBV virions. Next, to
show that infection by the EVþ fraction reﬂected an
EV-speciﬁc role, we investigated whether the transmission
of HBV was inhibited by the presence of neutralizing
antibodies—that is, whether pre-incubation with virus
(virion)-speciﬁc antibodies interfered with the infection
process. For virus entry analysis, the cells were collected at
3 hours postinfection and the viral DNA in cells was
analyzed. As shown in Figure 5B, HBV-DNA levels afterinfection with either Sup or EV- were inhibited signiﬁcantly
in the presence of neutralizing antibodies. In contrast, the
use of neutralizing antibodies did not decrease HBV-DNA
levels after infection with the EVþ fraction. In addition,
we analyzed the replication ability of HBV-containing EVs.
PXB-cells were infected with Sup, EV-, or EVþ to determine
whether HBV DNA transmitted by EVs supported viral
replication in the transmitted hepatocytes. Culture ﬂuid
from HBV-infected PXB-cells was collected for 22 days
postinfection, and the titer of viral DNA was quantiﬁed. The
viral DNA titer from EVþ-infected PXB-cells increased
10 Sanada et al Cellular and Molecular Gastroenterology and Hepatology Vol. -, No. -progressively over the course of the experiment; a similar
pattern was observed after infection with the other fractions
(Figure 5D). These results showed that the HBV DNA
derived from EV was replicative. Finally, to test whether
viral DNA is encapsidated or just attached to the membrane
of the EVs, we analyzed the DNase I resistance of the HBV
DNA carried by the EVþ fraction. As Figure 5E shows,
control DNA (naked DNA) subjected to DNase I treatment
was not detected by qPCR. In contrast, approximately 40%
of HBV DNA in the EVþ fraction was resistant to DNase I
treatment. This result indicated that at least 40% of HBV
DNA was encapsidated in EVs.
The results of this experimental series indicated that EVs
can transmit HBV infection even in the presence of
neutralizing antibodies, that is, via a non–virion-mediated
process (Figure 5E).Discussion
EVs are presumed to function primarily in intercellular
communication. These vesicles can inﬂuence the immune
system; act as signaling complexes; transfer receptors from
one cell to another; and convey speciﬁc mRNAs, microRNAs,
and proteins between cells, thereby impacting numerous
physiological processes.12–14 EVs also facilitate viral trans-
port, spread cell damage, and stimulate malignant trans-
formation.17 However, the role of EVs in HBV infection still
largely is unknown. The lack of a viral culture system
for HBV has hampered the evaluation of EV-mediated
transmission of HBV infection.
Several HBV culture systems have been used in previous
in vitro HBV analyses.25 Primary human hepatocytes and
primary tree shrew hepatocytes are susceptible to HBV
infection, but the limited availability of, and genetic varia-
tion among, such primary cells makes such culture systems
difﬁcult to use.29 Recent work has shown that sodium
taurocholate cotransporting polypeptide–overexpressing
cell lines show susceptibility to HBV infection and support
HBV propagation.30 However, the efﬁciency of HBV infection
and production in this cell line is reduced compared with
that in primary hepatocytes. In other work, Ishida et al23
reported that PXB-cells, which are primary hepatocytes
from chimeric mice, show high susceptibility to HBV infec-
tion and support persistent infection and viral production at
high titers (approximately 106 copies/mL in the superna-
tant). Furthermore, these cells are more readily available,
and show less genetic variation, than primary human or tree
shrew hepatocytes. Because PXB-cells are primary hepato-
cytes, the characteristics of these cells are assumed to better
resemble those of human hepatocytes compared with hep-
atoma cell lines. Taking these advantages into consideration,
we propose that the PXB-cell culture system currently is the
best model for analysis of the clinical effects of HBV.
By using this HBV infectious culture system, we showed
that the EV fraction derived from HBV-infected PXB-cells
contains abundant HBV DNA (representing 60% of all HBV
DNA in the culture supernatant), but is relatively depleted
for HBV RNA. We further showed that HBV-DNA–containing
EVs are capable of HBV transmission to naive PXB-cells.Several previous studies have reported that viral RNA is
transmitted via EVs,21,22 but this report shows that EVs
carry DNA as cargo and are capable of transmitting viral
DNA into hepatocytes.
Two major pathways have been implicated in exosome
generation: one is an ESCRT-mediated process,11,26 and the
other is a ceramide-triggered process.27 HBV core and L
envelope proteins have been shown to interact with the
ubiquitin-interacting adaptor, g2-adaptin, and the ubiquitin
ligase, Nedd4, in a process thought to regulate transport of
viral structures through an ESCRT-mediated process.8,9 In
contrast, a role for ceramide in HBV transmission has not
been reported. In the present study, we showed that
GW4869, an inhibitor of ceramide-triggered EVs, suppresses
HBV DNA in the cell supernatant but not in cells. Further-
more, GW4869 treatment decreases EV production. The
decrease of EV number in the supernatant was comparable
with the decrease in the level of HBV DNA in the EV fraction
(when values were normalized per milliliter of superna-
tant), suggesting that GW4869 suppresses the production of
HBV-DNA–containing EVs. Thus, HBV-DNA–containing EVs
appear to be generated through the ceramide-triggered
pathway, although the role of the ESCRT pathway in the
production of HBV-containing infectious EVs remains to be
elucidated. The combination of the present and previous
work shows that HBV exploits both sorting pathways,
with ESCRT-mediated processes used in the generation of
Dane particles and ceramide-triggered processes in the
generation of HBV-DNA–transmitting EVs.
We have shown here that the transmission of HBV DNA
to naive PXB-cells occurs via EV-enclosed HBV DNA, and
that this transmission is resistant to the effects of neutral-
izing antibodies. This observation is consistent with the lack
of HBsAg in HBV-DNA–transmitting EVs, as conﬁrmed by
STED microscopic analysis. It has been reported that 10%–
30% of newborns from HBsAg-/HBeAg-positive mothers
cannot be protected by passive/active vaccination alone and
become chronic HBV carriers.3 It also has been reported that
asymptomatic occult HBV infections are frequent even in
individuals who have protective levels of anti-HBs anti-
bodies.3 These reports implied that some virus evades
antibody neutralization. Our ﬁndings suggest that HBV-
containing infectious EVs may contribute to transmission
even in the presence of antibody neutralization, separate
from the effect of HBV S gene escape mutants.3
We showed that even in the presence of neutralizing anti-
body, 30% of the HBV inoculum still was capable of infecting
naive PXB-cells (Figure 4F), a process thought to be mediated
by HBV-DNA–transmitting EVs. Our DNase I treatment
experiment showed that although the viral DNA of Sup andEV-
were not degraded by the DNase I treatment, approximately
60% of the viral DNA of EVþ was degraded and 40% of the
viral DNAwas resistant (Figure 5E). This result was consistent
with the low efﬁciency of the attachment of EVþ to PXB-cells
(Figure 5B). Given that the HBV EVs in the Sup fraction were
completely resistant to DNase I treatment, we postulate that
the HBV EVs in the EVþ fraction may be damaged by the ul-
tracentrifugation step, and that this damage may affect the
efﬁciency of EV attachment to the hepatocytes.
- 2016 Transmission of HBV DNA by EVs 11After the inoculation of PXB-cells with EVþ, the viral DNA
level of the culture ﬂuid showed a gradual increase. This
observation suggested that HBV DNA transmitted by EVs
replicates in hepatocytes. Interestingly, although the EVþ
fraction showed a low efﬁciency of attachment to hepato-
cytes, the viral DNA level in the culture ﬂuid of PXB-cells
infectedwith EVþwas signiﬁcantly higher than the viral DNA
level in the culture ﬂuids of cells inoculated with Sup or
EV-. EV is known to contain various host factors (eg, micro-
RNAs), and these factors may enhance the initial replication
of HBV. Indeed, somemicroRNAs are reported to enhance the
replication of HBV.31,32 To clarify this point, further studies
focusing on HBV-DNA replication of EV will be needed.
In summary, we have shown, using primary hepatocytes
derived from humanized chimeric mouse, that HBV DNA-
containing EVs are generated through ceramide-triggered
vesicle formation, and that these EVs are infectious to pri-
mary hepatocytes. Furthermore, HBV transmission by these
EVs is resistant to antibody neutralization because these
vesicles lack HBs antigen, as shown by STED microscopic
analysis. These results suggest the existence of a separate
pathway for transmission of HBV; distinct strategies may be
needed to address HBV infection by this pathway.References
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